Compare Amphastar Pharmaceuticals Inc (AMPH) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Symbotic Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.34 (market cap $826.08M), while Symbotic Inc trades at $43.01 (market cap $5.55B). The key difference: Symbotic Inc is far larger — about 6.7× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | SYM | |
|---|---|---|
Market Cap | $826.08M | $5.55B |
Sector | Health | Technology |
52-Week High | $30.81 | $87.30 |
52-Week Low | $16.87 | $38.57 |
Enterprise Value | $1.22B | $3.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SYM trades at $43.64, up 1.14% with neutral technical signals. The company reported $2.25B revenue in 2025 but a net loss of $16.94M, though margins are improving. Recent acquisition of ARMS Innovations expands warehouse automation capabilities. Analyst consensus is bullish with a $57.50 price target, representing 32% upside potential from current levels.
Outlook remains positive due to strong revenue growth and expanding automation market, but profitability challenges and competitive pressures present risks. The stock offers growth potential but requires monitoring of earnings trajectory and market position in the evolving robotics sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
